Medical/Pharmaceuticals
Qilian International Holding Group Limited Received Approval for Oxytetracycline API Export to Egypt
JIUQUAN, China, Oct. 13, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that on September 14, 2021, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. (the "...
2021-10-13 20:00
2740
I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China
* Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myeloma (MM) * Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 * New IND application for combination of felz...
2021-10-13 20:00
1942
Shanghai, industry partners to co-build world-class biopharma industry cluster
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- This is a report from China.org.cn: The 2021 International Biopharma Industry Week opened in Shanghai on Oct. 11, bringing together industry gurus, research minds, investors, and government representatives to discuss the latest trends in the biopharmaceutic...
2021-10-13 19:43
1968
The CDE Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the Center for Drug Evaluation (CDE) NMPA has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with ...
2021-10-13 15:47
1735
World Thrombosis Day Campaign Unites Thousands of Global Partners to Shine a Spotlight on Blood Clots as an Urgent Health Problem
In its Eighth Year, the Global Campaign Aims to Increase Public Awareness of Blood Clots that Result from Hospitalization and COVID-19 CHAPEL HILL, N.C., Oct. 13, 2021 /PRNewswire/ -- Today, the World Thrombosis Day campaign encourages the public, healthcare professionals and policy makers to ke...
2021-10-13 14:19
2482
Gilead Sciences Partners with the International AIDS Society to Champion Stigma-free HIV Care Services in Asia and Latin America
SINGAPORE, Oct. 13, 2021 /PRNewswire/ -- Gilead Sciences, Inc. today announced
its partnership with IAS - the International AIDS Society - to expand theMe &
My Healthcare Provider campaign
2021-10-13 13:00
2115
New Dymax MD(R) 1040-M Autoclave Resistant Adhesive for Medical Instruments and Assembly
SINGAPORE, Oct. 13, 2021 /PRNewswire/ -- Dymax Corporation, leading manufacturer of rapid curing materials and equipment, unveils its newest product, 1040-M, as part of its MD® line of adhesives for medical device assembly applications. Designed to be autoclave resistant for more than 100 cycles...
2021-10-13 10:00
2603
SOPHiA GENETICS offers new genomic application for a deeper investigation of Mendelian diseases
SOPHiA Clinical Exome Solution v3 offers a streamlined end-to-end workflow to facilitate the assessment of challenging Mendelian disorders BOSTON and LAUSANNE, Switzerland, Oct. 13, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing...
2021-10-13 05:16
2800
Accelerate Innovation Towards the Future，SAB of Winhealth Pharma Formally Established
HANGZHOU, China, Oct. 12, 2021 /PRNewswire/ -- On October 12, 2021, Hong Kong Winhealth Pharma Group, (hereinafter referred to as "Winhealth Pharma") announced the formal establishment of its Scientific Advisory Board (SAB), aiming to further expand and optimize the Group's strategic layout in m...
2021-10-12 23:45
3354
DarwinHealth Announces Scientific Collaboration with Prelude Therapeutics to Develop Novel Biomarkers for Multiple Oncology Candidates
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing itsBiomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed ...
2021-10-12 22:52
3843
Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy
* Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors * Investment serves customers in addressing larger patient populations with new curative treatments * Enables suspension production of viral vectors up to...
2021-10-12 21:00
4298
CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan
TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed bySingapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients inJapan, today entered into an exclusive licensing agreement with Albireo Pharm...
2021-10-12 20:30
3585
Integrated Media Technology Limited Enters US$11 Million Conditional Agreement to Acquire an Internet of Medical Things (IoMT) Company
SYDNEY, Oct. 12, 2021 /PRNewswire/ -- Integrated Media Technology Limited (NASDAQ: IMTE) ("IMTE" or the "Company"), announces today the signing of a conditional sale and purchase agreement to acquire 100% equity interest in Magnum International Holdings Limited ("Magnum"), forUS$11 million which ...
2021-10-12 20:30
3033
CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan
TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed bySingapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients inJapan, today entered into an exclusive licensing agreement with Albireo Pharm...
2021-10-12 20:30
1735
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine
Agreement Expands on the Companies' Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies TORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle ce...
2021-10-12 20:23
3068
Shanghai Pharmaceuticals and Luca Healthcare Announce a Strategic Collaboration to Provide Home Drug Delivery to Rare Disease Patients on Luca Healthcare's Patient Management Platform
SHANGHAI, Oct. 12, 2021 /PRNewswire/ -- SPH Health Commerce, the Direct-to-Patient ("DTP") retail pharmacy subsidiary of Shanghai Pharmaceuticals and Luca Healthcare,China's category leader in clinically validated, software-based screening, treatment and management tools, today announced a strat...
2021-10-12 19:21
2984
NeoPlex (TM) HPV29 Detection, a new molecular detection kit from Genematrix, acquires European CE-IVD certification
* Real-time PCR-based human papillomavirus (HPV) detection product is launched. * Simultaneous HPV detection and genotyping of 29 HPV types are available. PANGYO,South Korea, Oct. 12, 2021 /PRNewswire/ -- Genematrix (KRX 109820), specialized in real-time PCR based molecular diagnostics, annou...
2021-10-12 16:00
2100
Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produc...
2021-10-12 10:30
3457
Ascletis Announces Results of the Phase IIa trial of ASC22 (Envafolimab) in Patients with Chronic Hepatitis B to be Presented in Oral Parallel Session at The Liver Meeting(R) 2021 by American Association for the Study of Liver Diseases
HANGZHOU and SHAOXING, China, Oct. 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that the results of Phase IIa trial of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B (CHB) will be presented in oral parallel session...
2021-10-12 08:30
4476
Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline
HANGZHOU, China and SAN FRANCISCO, Oct. 12, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the closing of an$70 million Series C financing. The f...
2021-10-12 08:00
4597
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 295 media titles]
2026-08-04 07:00
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
17451
